• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    7/6/23 9:12:39 AM ET
    $AEMD
    $ALLR
    $APLM
    $BDSX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Incannex Healthcare (NASDAQ:IXHL) stock rose 32.2% to $2.46 during Thursday's pre-market session. The market value of their outstanding shares is at $156.1 million.
    • Caribou Biosciences (NASDAQ:CRBU) shares rose 31.37% to $5.36. The market value of their outstanding shares is at $328.9 million.
    • Biodesix (NASDAQ:BDSX) stock rose 14.51% to $1.42. The market value of their outstanding shares is at $111.5 million.
    • iSpecimen (NASDAQ:ISPC) stock moved upwards by 12.02% to $1.49. The company's market cap stands at $13.4 million.
    • Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 11.76% to $0.38. The company's market cap stands at $9.4 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock rose 10.58% to $3.03. The market value of their outstanding shares is at $7.0 million.

    Losers

    • Allarity Therapeutics (NASDAQ:ALLR) stock fell 52.3% to $3.95 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 million.
    • Nymox Pharmaceutical (NASDAQ:NYMX) stock decreased by 16.87% to $0.21. The company's market cap stands at $18.8 million.
    • Nautilus Biotechnology (NASDAQ:NAUT) shares decreased by 12.78% to $3.21. The market value of their outstanding shares is at $400.8 million.
    • Calliditas Therapeutics (NASDAQ:CALT) stock decreased by 11.44% to $15.8. The company's market cap stands at $424.0 million.
    • Curis (NASDAQ:CRIS) stock fell 11.04% to $0.73. The market value of their outstanding shares is at $70.5 million.
    • Apollomics (NASDAQ:APLM) stock fell 10.88% to $5.0. The company's market cap stands at $447.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ALLR
    $APLM
    $BDSX

    CompanyDatePrice TargetRatingAnalyst
    Biodesix Inc.
    $BDSX
    2/27/2026Mkt Perform → Outperform
    William Blair
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Curis Inc.
    $CRIS
    5/19/2025$17.00Buy
    H.C. Wainwright
    Biodesix Inc.
    $BDSX
    5/14/2025Outperform → Mkt Perform
    William Blair
    Nautilus Biotechnology Inc.
    $NAUT
    12/5/2024$1.75Neutral → Sell
    Goldman
    Biodesix Inc.
    $BDSX
    9/16/2024Sector Outperform
    Scotiabank
    Biodesix Inc.
    $BDSX
    7/26/2024$3.00Buy
    Craig Hallum
    More analyst ratings

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Kelly Timothy P sold $12,020 worth of shares (6,228 units at $1.93), decreasing direct ownership by 8% to 73,125 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/27/26 4:01:13 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Technology Officer Kelly Timothy P was granted 45,000 shares and sold $6,168 worth of shares (3,147 units at $1.96), increasing direct ownership by 112% to 79,353 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:41 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Mcclung Barbara G was granted 45,000 shares and sold $13,598 worth of shares (6,938 units at $1.96), increasing direct ownership by 9% to 481,564 units (SEC Form 4)

    4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

    2/24/26 8:54:36 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix upgraded by William Blair

    William Blair upgraded Biodesix from Mkt Perform to Outperform

    2/27/26 8:20:07 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    SEC Filings

    View All

    SEC Form S-8 filed by Nautilus Biotechnology Inc.

    S-8 - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    2/26/26 4:27:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-K filed by Nautilus Biotechnology Inc.

    10-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    2/26/26 4:11:59 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-K filed by Biodesix Inc.

    10-K - BIODESIX INC (0001439725) (Filer)

    2/26/26 4:06:05 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Marketing Officer Suzuki Kentaro bought $5,960 worth of shares (4,000 units at $1.49) (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    11/10/25 9:29:14 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

    2/26/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AEMD
    $ALLR
    $APLM
    $BDSX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

    Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/20/21 3:40:41 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

    2/26/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALLR
    $APLM
    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Caribou Biosciences Inc.

    SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    12/6/24 4:06:56 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Caribou Biosciences Inc.

    SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

    11/14/24 7:53:54 PM ET
    $CRBU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care